Neuronetics Management

Management criteria checks 1/4

Neuronetics' CEO is Keith Sullivan, appointed in Jul 2020, has a tenure of 3.75 years. total yearly compensation is $2.99M, comprised of 23.4% salary and 76.6% bonuses, including company stock and options. directly owns 2.21% of the company’s shares, worth €2.16M. The average tenure of the management team and the board of directors is 1.2 years and 3.9 years respectively.

Key information

Keith Sullivan

Chief executive officer

US$3.0m

Total compensation

CEO salary percentage	23.4%
CEO tenure	3.8yrs
CEO ownership	2.2%
Management average tenure	1.2yrs
Board average tenure	3.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Keith Sullivan's remuneration changed compared to Neuronetics's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$3m	US$700k	-US$30m
Sep 30 2023	n/a	n/a	-US$33m
Jun 30 2023	n/a	n/a	-US$31m
Mar 31 2023	n/a	n/a	-US$37m
Dec 31 2022	US$2m	US$676k	-US$37m
Sep 30 2022	n/a	n/a	-US$37m
Jun 30 2022	n/a	n/a	-US$37m
Mar 31 2022	n/a	n/a	-US$34m
Dec 31 2021	US$3m	US$650k	-US$31m
Sep 30 2021	n/a	n/a	-US$27m
Jun 30 2021	n/a	n/a	-US$22m
Mar 31 2021	n/a	n/a	-US$23m
Dec 31 2020	US$4m	US$280k	-US$27m

Compensation vs Market: Keith's total compensation ($USD2.99M) is above average for companies of similar size in the German market ($USD401.52K).

Compensation vs Earnings: Keith's compensation has increased whilst the company is unprofitable.

CEO

Keith Sullivan (65 yo)

3.8yrs

Tenure

US$2,990,985

Compensation

Mr. Keith J. Sullivan has been President, Chief Executive Officer and Director of Neuronetics, Inc. since July 14, 2020. Mr. Sullivan has been a Director of Venus Concept Inc. (formerly known as Restoratio...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Keith Sullivan	President	3.8yrs	US$2.99m	2.21% $ 2.2m
Stephen Furlong	Executive VP	4.8yrs	US$1.36m	0.85% $ 829.6k
W. Macan	Executive VP	4.3yrs	US$1.16m	0.60% $ 587.4k
Rusty Page	Senior VP of Operations & Quality	1.3yrs	no data	no data
Lisa Metzner-Rosas	Senior VP & Chief Marketing Officer	less than a year	no data	no data
Sara Grubbs	Senior VP & Chief Revenue Officer	1.2yrs	no data	no data
Rick Grubbs	Senior Vice President of National Accounts	1.2yrs	no data	no data
Cory Anderson	Senior Vice President of R&D and Clinical	1.2yrs	no data	no data

1.2yrs

Average Tenure

59yo

Average Age

Experienced Management: NRC's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Keith Sullivan	President	3.8yrs	US$2.99m	2.21% $ 2.2m
Glenn Muir	Independent Director	6.8yrs	US$182.50k	0.43% $ 417.6k
Wilfred Jaeger	Independent Director	18.9yrs	US$162.50k	0.34% $ 332.7k
Sheryl Conley	Independent Director	4.5yrs	US$175.00k	0.26% $ 255.8k
John Bakewell	Independent Director	4yrs	US$180.00k	0.26% $ 253.9k
Robert Cascella	Independent Chairman of the Board	3yrs	US$245.00k	0.30% $ 289.4k
Joseph Capper	Director	1.3yrs	US$165.00k	0.023% $ 22.1k
Megan Rosengarten	Independent Director	2.7yrs	US$162.50k	0.17% $ 161.2k

3.9yrs

Average Tenure

63yo

Average Age

Experienced Board: NRC's board of directors are considered experienced (3.9 years average tenure).

Neuronetics Management

Management criteria checks 1/4

Key information

Recent management updates

President recently sold €66k worth of stock

President recently sold €55k worth of stock

Executive VP recently sold €55k worth of stock

President recently sold €200k worth of stock

Neuronetics Announces Elevation of Sara Grubbs to SVP, Chief Revenue Officer

High number of new directors

Recent updates

Neuronetics, Inc. to Report Q1, 2024 Results on May 07, 2024

Neuronetics, Inc. Announces the Publication of Significant Clinical Findings in Brain Stimulation: Basic, Translational, and Clinical Research in Neuromodulation

Neuronetics, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024

Full year 2023 earnings released: US$1.05 loss per share (vs US$1.38 loss in FY 2022)

President recently sold €66k worth of stock

Neuronetics, Inc. to Report Q4, 2023 Results on Mar 05, 2024

Neuronetics, Inc. to Report Q4, 2023 Results on Mar 05, 2024

Neuronetics Launches Latest Evolution in Its Trakstar® Patient Data Management System

President recently sold €55k worth of stock

Neuronetics, Inc. Revises Earnings Guidance for the Fourth Quarter and Full Year of 2023

Neuronetics Receives 510(K) Clearance for Neurosite Coil Placement Accessory

Neuronetics, Inc. Announces Pharmaceuticals and Medical Devices Agency Approval in Japan

Neuronetics, Inc. Announces Pharmaceuticals and Medical Devices Agency Approval in Japan

Neuronetics, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2023

Third quarter 2023 earnings released: US$0.33 loss per share (vs US$0.28 loss in 3Q 2022)

Neuronetics, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Neuronetics, Inc. Announces the Launch of the NeuroStar Voices Portal

Neuronetics, Inc. Provides Revenue Guidance for the Third Quarter of 2023

Second quarter 2023 earnings released: US$0.17 loss per share (vs US$0.39 loss in 2Q 2022)

Neuronetics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Neuronetics, Inc Announces Expanded TMS Therapy Access Through Aetna® Health Plans

Neuronetics Receives 510(K) Clearance for Ocd Mt Cap for Neurostar Advanced Therapy

First quarter 2023 earnings released: US$0.38 loss per share (vs US$0.41 loss in 1Q 2022)

Neuronetics, Inc. Provides Earnings Guidance for the Second Quarter and Full Year of 2023

Executive VP recently sold €55k worth of stock

Full year 2022 earnings released: US$1.38 loss per share (vs US$1.22 loss in FY 2021)

President recently sold €200k worth of stock

Neuronetics Announces Elevation of Sara Grubbs to SVP, Chief Revenue Officer

High number of new directors

High number of new directors

Senior VP recently sold €91k worth of stock

Neuronetics, Inc. Announces Data Confirming Efficacy in Treating Anxious Depression with NeuroStar(R) Advanced Therapy for Mental Health

Neuronetics, Inc. Revised Revenue Guidance for the Fourth Quarter and Full Year of 2022

Neuronetics, Inc. Appoints Joseph H. Capper to Its Board of Directors and as Member of the Audit Committee, Effective January 1, 2023

Neuronetics, Inc. Announces New Advancements of NeuroStar Advanced Therapy System

Third quarter 2022 earnings released: US$0.28 loss per share (vs US$0.31 loss in 3Q 2021)

Neuronetics, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2022

Neuronetics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Neuronetics, Inc. Launches Innovations to Neurostar Advanced Therapy’s Proprietary Trakstar Platform

Bruce J. Shook Notifies the Board of Directors of Neuronetics, Inc. to Resign from the Board Effective as of October 31, 2022

Second quarter 2022 earnings released: US$0.39 loss per share (vs US$0.29 loss in 2Q 2021)

Neuronetics, Inc. Provides Earnings Guidance for the Quarter Ending September 30, 2022 and for the Year Ending December 31, 2022

President recently sold €232k worth of stock

Neurostics Inc. Receives U.S. Food and Drug Administration Clearance for Treatment of Anxious Depression

Cannell Capital LLC Communicates with Neuronetics Inc

First quarter 2022 earnings released: US$0.41 loss per share (vs US$0.31 loss in 1Q 2021)

Neuronetics, Inc. Provides Earning Guidance for the Second Quarter and Full Year of 2022

Neurostar® Advanced Therapy for Mental Health Receives FDA Clearance for Treatment of Obsessive-Compulsive Disorder

High number of new directors

Neuronetics, Inc., Annual General Meeting, May 26, 2022

Neuronetics, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Neuronetics, Inc. Announces the Commercial Launch of the MT Cap in the U.S

Neuronetics, Inc. to Report Q4, 2021 Results on Mar 08, 2022

Senior VP recently sold €56k worth of stock

Neuronetics, Inc. Updates Earnings Guidance for the Fourth Quarter and Full Year of 2021

Neuronetics, Inc. Announces 510(k) Clearance of MT Cap Technology for NeuroStar Advanced Therapy for Mental Health

Independent Chairman of the Board recently bought €55k worth of stock

Third quarter 2021 earnings released: US$0.31 loss per share (vs US$0.18 loss in 3Q 2020)

Neuronetics, Inc Announces New Data Highlights NeuroStar® Advanced Therapy for Mental Health Safety Over H-Coil TMS

Independent Chairman of the Board recently bought €85k worth of stock

Second quarter 2021 earnings released: US$0.29 loss per share (vs US$0.41 loss in 2Q 2020)

Senior VP recently sold €73k worth of stock

President recently sold €581k worth of stock

Independent Chairman Brian Farley has left the company

Independent Director recently sold €77k worth of stock

First quarter 2021 earnings released: US$0.31 loss per share (vs US$0.68 loss in 1Q 2020)

Neuronetics Reports revenue guidance for the year 2021

Neuronetics to Present Clinical Data At the American Psychiatric Association 2021 Annual Meeting